Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Net Cash Flow (2016 - 2025)

Angiodynamics (ANGO) has disclosed Net Cash Flow for 16 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow rose 582.49% year-over-year to $2.9 million, compared with a TTM value of -$13.2 million through Nov 2025, down 101.15%, and an annual FY2025 reading of -$20.6 million, down 165.67% over the prior year.
  • Net Cash Flow was $2.9 million for Q4 2025 at Angiodynamics, up from -$17.3 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $17.6 million in Q1 2024 and bottomed at -$21.2 million in Q3 2024.
  • Average Net Cash Flow over 5 years is -$830650.0, with a median of -$788500.0 recorded in 2021.
  • Peak annual rise in Net Cash Flow hit 10549.7% in 2024, while the deepest fall reached 263.41% in 2024.
  • Year by year, Net Cash Flow stood at -$966000.0 in 2021, then soared by 628.57% to $5.1 million in 2022, then tumbled by 38.88% to $3.1 million in 2023, then plummeted by 119.58% to -$611000.0 in 2024, then soared by 582.49% to $2.9 million in 2025.
  • Business Quant data shows Net Cash Flow for ANGO at $2.9 million in Q4 2025, -$17.3 million in Q3 2025, and $10.4 million in Q2 2025.